{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:34:36Z","timestamp":1774017276430,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.meegid.2022.105358","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T10:58:20Z","timestamp":1661943500000},"page":"105358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Frequency of genotypic factors possibly associated with cabotegravir\/rilpivirine failure in antiretroviral treatment-na\u00efve and -experienced HIV-1- infected population"],"prefix":"10.1016","volume":"104","author":[{"given":"Kaja","family":"Scheibe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Urba\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karol","family":"Serwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi\u0142osz","family":"Parczewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.meegid.2022.105358_bb0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/PPA.S192735","article-title":"Adherence to HIV treatment regimens: systematic literature review and meta-analysis","volume":"13","author":"Altice","year":"2019","journal-title":"Patient Prefer Adherence."},{"issue":"1","key":"10.1016\/j.meegid.2022.105358_bb0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/COH.0000000000000708","article-title":"A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV","volume":"17","author":"Bares","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"11","key":"10.1016\/j.meegid.2022.105358_bb0015","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1093\/jac\/dkab161","article-title":"Prevalence of genotypic baseline risk factors for cabotegravir+rilpivirine failure among ARV-naive patients","volume":"76","author":"Charpentier","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.meegid.2022.105358_bb0020","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS."},{"key":"10.1016\/j.meegid.2022.105358_bb0025","series-title":"Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084. HIVR4P (HIV Research for Prevention) Virtual, 27\u201328 January and 3\u20134 February","author":"Delany-Moretlwe","year":"2021"},{"issue":"2","key":"10.1016\/j.meegid.2022.105358_bb0030","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/infdis\/jiab360","article-title":"Swiss HIV cohort study. Increasing frequency and transmission of HIV-1 non-B subtypes among men who have sex with men in the Swiss HIV Cohort Study","volume":"225","author":"Duran Ramirez","year":"2022","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.meegid.2022.105358_bb0035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2022.105358_bb0040","series-title":"Updated efficacy, safety, and case studies in HPTN 083: CAB-LA vs TDF\/FTC for PrEP. Conference on Retroviruses and Opportunistic Infections; February 12\u201316","author":"Landovitz","year":"2022"},{"issue":"1","key":"10.1016\/j.meegid.2022.105358_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209605","article-title":"German HIV-1 Seroconverter Study Group. Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort","volume":"14","author":"Machnowska","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.meegid.2022.105358_bb0050","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/molbev\/msu300","article-title":"IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies","volume":"32","author":"Nguyen","year":"2015","journal-title":"Mol. Biol. Evol."},{"issue":"4","key":"10.1016\/j.meegid.2022.105358_bb0055","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.meegid.2022.105358_bb0060","series-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months: ATLAS-2M week 152 results. Conference on Retroviruses and Opportunistic Infections; February 12\u201316","author":"Overton","year":"2022"},{"issue":"8","key":"10.1016\/j.meegid.2022.105358_bb0065","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/jmv.21797","article-title":"Characteristics of HIV-1 non-B subtype infections in Northwest Poland","volume":"82","author":"Parczewski","year":"2010","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.meegid.2022.105358_bb0070","doi-asserted-by":"crossref","first-page":"18929","DOI":"10.7448\/IAS.17.1.18929","article-title":"Transmitted drug resistance to rilpivirine among antiretroviral-na\u00efve patients living with HIV from northern Poland","volume":"17","author":"Parczewski","year":"2014","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.meegid.2022.105358_bb0075","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.meegid.2016.02.001","article-title":"Distribution and time trends of HIV-1 variants in Poland: characteristics of non-B clades and recombinant viruses","volume":"39","author":"Parczewski","year":"2016","journal-title":"Infect. Genet. Evol."},{"issue":"1","key":"10.1016\/j.meegid.2022.105358_bb0080","doi-asserted-by":"crossref","first-page":"12734","DOI":"10.1038\/s41598-021-92210-2","article-title":"Transmitted HIV drug resistance and subtype patterns among blood donors in Poland","volume":"11","author":"Parczewski","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.meegid.2022.105358_bb0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/13596535211043044","article-title":"Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)\u2013infected patients","author":"Scheibe","year":"2021","journal-title":"Antivir. Ther."},{"issue":"1","key":"10.1016\/j.meegid.2022.105358_bb0090","doi-asserted-by":"crossref","first-page":"16609","DOI":"10.1038\/s41598-021-96125-w","article-title":"Molecular epidemiology and HIV-1 variant evolution in Poland between 2015 and 2019","volume":"11","author":"Serwin","year":"2021","journal-title":"Sci. Rep."},{"issue":"18","key":"10.1016\/j.meegid.2022.105358_bb0095","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku739","article-title":"COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification","volume":"42","author":"Struck","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.meegid.2022.105358_bb0100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS."},{"issue":"7","key":"10.1016\/j.meegid.2022.105358_bb0105","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1093\/molbev\/msab120","article-title":"MEGA11: molecular evolutionary genetics analysis version 11","volume":"38","author":"Tamura","year":"2021","journal-title":"Mol. Biol. Evol."},{"issue":"2","key":"10.1016\/j.meegid.2022.105358_bb0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jviromet.2008.07.008","article-title":"A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes","volume":"153","author":"Van Laethem","year":"2008","journal-title":"J. Virol. Methods"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134822001551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134822001551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:54:49Z","timestamp":1761576889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134822001551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":22,"alternative-id":["S1567134822001551"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2022.105358","relation":{},"ISSN":["1567-1348"],"issn-type":[{"value":"1567-1348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency of genotypic factors possibly associated with cabotegravir\/rilpivirine failure in antiretroviral treatment-na\u00efve and -experienced HIV-1- infected population","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2022.105358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105358"}}